Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on Ocular Therapeutix (OCUL) to $29 from $20 and keeps an Outperform rating on the shares. New details on a derisked pivotal program in Nonproliferative Diabetic Retinopathy allows value to be ascribed to the potential blockbuster opportunity while the wet AMD pivotal readouts will drive near-term value creation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Ocular Therapeutix’s Strategic Initiatives and Clinical Advancements Drive Buy Rating
- Ocular Therapeutix Announces $475M Stock Offering
- Ocular Therapeutix prices 37.9M shares at $12.53 in underwritten offering
- Ocular Therapeutix Updates on AXPAXLI Clinical Trials
- Ocular Therapeutix files automatic mixed securities shelf